# Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology

> **NCT05046782** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Prostate Cancer

## Interventions

- **DEVICE:** restriction spectrum imaging (RSI)

## Key facts

- **NCT ID:** NCT05046782
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-02-28
- **Primary completion:** 2027-02-02
- **Final completion:** 2027-02-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn prior to full implementation due to logistical and resource-related considerations. Study procedures are currently under review and a new protocol may be considered pending the outcome of this review
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05046782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05046782, "Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05046782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*